uniQure N.V — Liquidità Trimestrale (NASDAQ:QURE) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 556.54 M605.4 M584.89 M888.38 M824.91 M Totale passività 563.29 M571.72 M588.89 M659.64 M626.01 M Patrimonio netto totale -6.75 M33.69 M-4 M228.75 M198.9 M Totale passività e patrimonio netto 556.54 M605.4 M584.89 M888.38 M824.91 M Debito totale 51.32 M51.59 M51.84 M51.88 M49.7 M Indebitamento netto -316.36 M-357.43 M-325.3 M-642.42 M-573.15 M

uniQure N.V

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

Notizie

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Mizuho alza il rating di uniQure dopo il cambio ai vertici FDA

Mizuho upgrades uniQure stock rating on FDA leadership change

Avago, Lumentum among market cap stock movers on Monday

Chardan alza il target su uniQure dopo il cambio ai vertici della FDA

Chardan raises uniQure stock price target on FDA leadership change

Tesla and Facebook among market cap stock movers on Monday

Biotech Stocks Pop After CBER Chief Exit - Moderna (NASDAQ:MRNA)